Neoscreen was founded in 2007 and it is involved in the development and application of genetics testregarding prenatal testing, carrier screening (testing for future parents), hereditary cancer syndromes,congenital heart diseases, pharmacogenomics profiling (effect of genotype on drug response) aswell as expanded neonatal screening. In addition, Neoscreen offers whole genome sequencing as adiagnostic tool for serious diseases. Since its establishment it collaborates with private hospitals(IASO, IASO Thesallia, REA, GAIA, EUROPEAN INTERBALKAN MEDICAL CENTER), In Vitro Fertilization (IVF) centers, doctors, stem cell companies (Omnigen), the Breast Center in Ippokrateio Hospital under the direction of Professor Mr. G.Zografos, with EKKAN, the Congenital Heart Diseases Center in Ippokrateio Hospital under the direction of Dr. A. Anastasakis and professor Mr. X. Stefanades, providing services of high quality. A total of more than 80.000 newborns have been subjected to Neonatal Testing and more than 7.000 adults per year are being subjected to genetic tests (for Cystic Fibrosis, Thrombophilia, Thalassemia, Spinal Muscular Atrophy, BRCAs, Hypertrophiccardiomyopathy, Whole Exome Sequencing etc.). Neoscreen employs high level personnel and ownsequipment of the latest technology. The most of our tests are accredited by the Hellenic AccreditationSystem (E.SY.D.) according to the international standards ISO 17025 & ISO 15189. As part of theaccreditation, it is subjected to external quality control by the CDC (Center for Disease Control &Prevention) and the Instant eV, with 100% success.